enGene Therapeutics Inc. (ENGN)Healthcare | Biotechnology | Montreal, Canada | NasdaqCM
1.86 USD
-0.04
(-2.105%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.85 -0.01 (-0.010%) ⇩ (July 13, 2026, 7:37 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:40 a.m. EDT
The investment case for enGene Therapeutics is currently broken by a perfect storm of deteriorating clinical data, legal entanglements, and a catastrophic multi-year price collapse. While the company holds a fortress-like balance sheet with significant cash reserves relative to its debt, the business fundamentals are failing to generate value, evidenced by a 67% drop in share price over the last three years and double-digit losses in both assets and equity. The recent mixed results from the LEGEND trial have shattered the bull case, triggering a massive exodus of capital. Options markets confirm this pessimism, with traders aggressively buying deep out-of-the-money puts while ignoring calls entirely. Despite the attractive book value and low enterprise-to-EBITDA ratio, these metrics are irrelevant for a biotech firm with no earnings and a shrinking market cap; the market is correctly pricing in a high probability of further decline until a definitive positive catalyst emerges. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 1.419096 |
| MSTL | 1.430804 |
| AutoETS | 1.433823 |
| AutoARIMA | 1.461019 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 23% |
| H-stat | 0.98 |
| Ljung-Box p | 0.127 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 15.95 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 13.07 |
| Market Cap | 124,600,400 |
| Forward P/E | -1.32 |
| Beta | -0.28 |
| Previous Name | enGene Holdings Inc. |
| Website | https://www.engene.com |
As of July 11, 2026, 6:40 a.m. EDT: Speculators are overwhelmingly bearish, positioning heavy out-of-the-money puts at strikes of $1.00 and $2.00 across multiple expirations, while call activity is virtually nonexistent. This asymmetry suggests a strong expectation of further downside or a 'long gamma' squeeze scenario where sellers are hedging against potential volatility spikes.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.43113774 |
| Address1 | 4,868 Rue Levy |
| Address2 | Suite 220 |
| All Time High | 47.17 |
| All Time Low | 1.4 |
| Ask | 2.35 |
| Ask Size | 2 |
| Average Analyst Rating | 2.7 - Hold |
| Average Daily Volume10 Day | 1,282,840 |
| Average Daily Volume3 Month | 1,884,783 |
| Average Volume | 1,884,783 |
| Average Volume10Days | 1,282,840 |
| Beta | -0.275 |
| Bid | 1.36 |
| Bid Size | 2 |
| Book Value | 3.809 |
| City | Montreal |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.86 |
| Current Ratio | 12.567 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.89 |
| Day Low | 1.835 |
| Debt To Equity | 13.07 |
| Display Name | enGene Therapeutics |
| Earnings Timestamp | 1,781,526,600 |
| Earnings Timestamp End | 1,789,389,000 |
| Earnings Timestamp Start | 1,789,389,000 |
| Ebitda | -131,911,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.762 |
| Enterprise Value | -100,513,592 |
| Eps Current Year | -1.72709 |
| Eps Forward | -1.4049 |
| Eps Trailing Twelve Months | -2.18 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.4252 |
| Fifty Day Average Change | -0.5652 |
| Fifty Day Average Change Percent | -0.23305294 |
| Fifty Two Week Change Percent | -43.113773 |
| Fifty Two Week High | 12.25 |
| Fifty Two Week High Change | -10.39 |
| Fifty Two Week High Change Percent | -0.8481633 |
| Fifty Two Week Low | 1.4 |
| Fifty Two Week Low Change | 0.46000004 |
| Fifty Two Week Low Change Percent | 0.32857147 |
| Fifty Two Week Range | 1.4 - 12.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,643,725,800,000 |
| Float Shares | 22,487,024 |
| Forward Eps | -1.4049 |
| Forward P E | -1.3239377 |
| Free Cashflow | -69,263,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 81 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00093000004 |
| Held Percent Institutions | 1.00301 |
| Implied Shares Outstanding | 66,989,466 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-11-01 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,761,868,800 |
| Long Business Summary | enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada. |
| Long Name | enGene Therapeutics Inc. |
| Market | us_market |
| Market Cap | 124,600,400 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_9516520 |
| Most Recent Quarter | 1,777,507,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -126,850,000 |
| Next Fiscal Year End | 1,793,404,800 |
| Non Diluted Market Cap | 127,614,932 |
| Number Of Analyst Opinions | 7 |
| Open | 1.92 |
| Operating Cashflow | -109,997,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 514 332 4888 |
| Post Market Change | -0.00999999 |
| Post Market Change Percent | -0.5376339 |
| Post Market Price | 1.85 |
| Post Market Time | 1,783,985,878 |
| Prev Name | enGene Holdings Inc. |
| Previous Close | 1.9 |
| Price Eps Current Year | -1.076956 |
| Price Hint | 4 |
| Price To Book | 0.48831713 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.166 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.7 |
| Region | US |
| Regular Market Change | -0.04 |
| Regular Market Change Percent | -2.10526 |
| Regular Market Day High | 1.89 |
| Regular Market Day Low | 1.835 |
| Regular Market Day Range | 1.835 - 1.89 |
| Regular Market Open | 1.92 |
| Regular Market Previous Close | 1.9 |
| Regular Market Price | 1.86 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,049,165 |
| Return On Assets | -0.28863 |
| Return On Equity | -0.52585 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 66,989,466 |
| Shares Percent Shares Out | 0.017 |
| Shares Short | 1,141,694 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,622,269 |
| Short Name | enGene Therapeutics Inc. |
| Short Percent Of Float | 0.021 |
| Short Ratio | 1.15 |
| Source Interval | 15 |
| State | QC |
| Symbol | ENGN |
| Target High Price | 5.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 3.28571 |
| Target Median Price | 4.0 |
| Total Cash | 258,464,992 |
| Total Cash Per Share | 3.858 |
| Total Debt | 33,351,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.18 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.808425 |
| Two Hundred Day Average Change | -4.948425 |
| Two Hundred Day Average Change Percent | -0.726809 |
| Type Disp | Equity |
| Volume | 1,049,165 |
| Website | https://www.engene.com |
| Zip | H4R 2P1 |